BeStock  
Stocks › Biotechnology › ASND

Ascendis Pharma A/S ASND

US equityMarket cap rank #1027Biotechnology
$252.73 −$3.23 (-1.26%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $252.73 0.00%
Open$255.44
Prev close$255.96
Day range$251.55 – $256.65
Volume602.9K
Market cap$16.63B
P/E (TTM)34.7
Dividend yield–

Earnings

Average move on report day±4.2%last 16 reports
Closed higher9 of 1656% of the time
Best reaction+13.0%
Worst reaction-11.3%

Stock move on the day after each report

0.0%2023/Q4-2.8%2024/Q1-11.3%2024/Q2+1.8%2024/Q3+13.0%2024/Q4+2.7%2025/Q1+0.6%2025/Q2+3.6%2025/Q3-1.5%2025/Q4+4.3%2026/Q1-3.6%2026/Q2+3.0%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q312 Nov 2026Pre Market±5.2%+3.00%Within range
2026/Q213 Aug 2026Pre Market±6.2%-3.61%Within range
2026/Q17 May 2026Pre Market±7.6%+4.34%Within range
2025/Q411 Feb 2026After Market±6.2%-1.53%Within range
2025/Q312 Nov 2025After Market±8.2%+3.63%Within range
2025/Q27 Aug 2025After Market±12.0%+0.60%Within range
2025/Q11 May 2025After Market±10.4%+2.74%Within range
2024/Q412 Feb 2025After Market±7.9%+12.96%Bigger than priced
2024/Q314 Nov 2024After Market±21.0%+1.79%Within range
2024/Q23 Sep 2024After Market±9.9%-11.27%Bigger than priced
2024/Q12 May 2024After Market±21.8%-2.76%Within range
2023/Q47 Feb 2024After Market±10.4%-0.03%Within range
2023/Q37 Nov 2023After Market±9.5%-1.47%Within range
2023/Q25 Sep 2023After Market±15.2%+4.24%Within range
2023/Q127 Apr 2023After Market±19.3%-9.12%Within range
2022/Q416 Feb 2023After Market–+4.75%–

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q3

By business line

  • YORVIPATH€290.63M 78.6%
  • SKYTROFA€59.42M 16.1%
  • YUVIWEL€15.64M 4.2%
  • Licenses, services and clinical supply€3.97M 1.1%

Latest reported quarter: Q3, ended Sep 2026 · reported in EUR

Revenue€369.66M+73.0% YoY
Operating profit€124.58M+1,032.8% YoY
Net profit€73.97M+221.3% YoY
Diluted EPS€1.08+208.0% YoY
Free cash flow€186.03M+8,758.6% YoY
Operating cash flow€188.79M

Revenue, last 8 quarters

€173.9MDec '24€101.0MMar '25€158.0MJun '25€213.6MSep '25€247.5MDec '25€246.6MMar '26€339.3MJun '26€369.7MSep '26

Net profit, last 8 quarters

€-38.5MDec '24€-94.6MMar '25€-38.9MJun '25€-61.0MSep '25€-33.6MDec '25€629.3MMar '26€207.0MJun '26€74.0MSep '26

Profitability & balance sheet

Gross margin91.9%
Operating margin31.3%
Net margin72.9%
Return on equity132.2%
Return on assets49.0%
Return on invested capital69.9%
Current ratio2.89
Liabilities / assets38.2%
Cash & investments€964.36M
Total debt€447.81M
Net cash (debt)€516.56M
Free cash flow / sales43.1%

Discussion

No comments yet — be the first to weigh in on ASND.

Sign in to join the discussion.

Scroll to Top